Home Newsfeeds RBC Capital Maintains Outperform on CrowdStrike Holdings, Lowers Price Target to $200

RBC Capital Maintains Outperform on CrowdStrike Holdings, Lowers Price Target to $200

RBC Capital analyst Matthew Hedberg maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Outperform and lowers the price target from $236 to $200.

byBenzinga Newsdesk

November 28, 2022

1 minute read

RBC Capital analyst Matthew Hedberg maintains CrowdStrike Holdings (NASDAQ:CRWD) with a Outperform and lowers the price target from $236 to $200.

News

PCTEL Receives FCC Regulatory Certification For New Industrial IoT Radio Module

By Benzinga Newsdesk

September 15, 8:54 AM

PCTEL, Inc. (NASDAQ:PCTI), a leading global provider of wireless technology solutions, today announced receipt of certification from the Federal Communications Commission ("FCC") for its Industrial IoT Radio

PCTI

Lumos Pharma Announces New Data And Analysis Of 15 Subjects From OraGrowtH212 Trial Presented At The 2023 ESPE Annual Meeting

By Benzinga Newsdesk

September 26, 9:20 AM

Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal ChildrenAnalysis Shows Annualized Height Velocity Increased ~62% Compared to BaselineData Support LUM-201 Mechanism of

LUMO

Cowen & Co. Downgrades Sea to Market Perform, Lowers Price Target to $60

By Benzinga Newsdesk

November 22, 5:58 AM

Cowen & Co. analyst John Blackledge downgrades Sea (NYSE:SE) from Outperform to Market Perform and lowers the price target from $72 to $60.

Amneal Reports Preliminary Q1 Revenue of $550M-$560M

By Benzinga Newsdesk

April 17, 6:33 AM

Based on preliminary financial information, Amneal expects to report: Net revenue of $550 million to $560 million, an increase of approximately 12% compared to the first quarter of

AMRX

RBC Capital Maintains Outperform on CrowdStrike Holdings, Lowers Price Target to $200

Related Posts

PCTEL Receives FCC Regulatory Certification For New Industrial IoT Radio Module

Lumos Pharma Announces New Data And Analysis Of 15 Subjects From OraGrowtH212 Trial Presented At The 2023 ESPE Annual Meeting

Cowen & Co. Downgrades Sea to Market Perform, Lowers Price Target to $60

Amneal Reports Preliminary Q1 Revenue of $550M-$560M